Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 December 2025, 14:00 (CET) to 18 December 2025, 15:00 (CET)

Medical devices

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Bosulif, bosutinib, Date of authorisation: 27/03/2013, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Abilify, aripiprazole, Date of authorisation: 04/06/2004, Revision: 50, Status: Authorised

Human medicines European public assessment report (EPAR): Xeljanz, tofacitinib, Date of authorisation: 22/03/2017, Date of refusal: 25/04/2013, Revision: 36, Status: Authorised

Substance and product data management services

Human medicines European public assessment report (EPAR): Tremfya, guselkumab, Date of authorisation: 10/11/2017, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Hepcludex, bulevirtide, Date of authorisation: 31/07/2020, Revision: 16, Status: Authorised

IRIS guide for applicants - How to create, submit and manage IRIS applications, for industry and individual applicants